comparemela.com
Home
Live Updates
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 : comparemela.com
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML
Related Keywords
United States ,
California ,
San Diego ,
Brisbane ,
Queensland ,
Australia ,
American ,
Corey Davis ,
Jeffrey Miller ,
Christina Tartaglia ,
Stern Investor Relations Inc ,
Ernestn Morial Convention Center ,
Nasdaq ,
Fate Therapeutics Inc ,
American Society Of Hematology ,
Exchange Commission ,
University Of Minnesota ,
Gt Biopharma Inc ,
Masonic Cancer Center ,
American Society ,
Annual Meeting ,
Tri Specific Killer Engager ,
Fate Therapeutics ,
Effectively Recognize ,
Heterogeneous Population Associated ,
Deputy Director ,
Consulting Chief Scientific Officer ,
Heterogenous Population Associated ,
Convention Center ,
New Orleans ,
Blood Advances ,
Private Securities Litigation Reform Act ,
Investor Relations Contact ,
Therapeuticsinvestor Relations Contact ,
Investor Relations ,
Biotechnology ,
Cancer ,
Cancer Treatments ,
Immune System ,
Immunology ,
Medical Specialties ,
Medicine ,
Therapeutics ,
Branches Of Biology ,
Cancer Immunotherapy ,
Chimeric Antigen Receptort Cell ,
Lymphoma ,
Monoclonal Antibody ,
Natural Killer Cell ,
comparemela.com © 2020. All Rights Reserved.